Concepedia

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma

Mohammad Atefi, Bjoern Titz, Earl Avramis, Charles Ng, Deborah J. Wong, Amanda Lassen, Michael Cerniglia, Helena Escuin-Ordinas, David Foulad, Begonya Comin-Anduix,

Molecular Cancer · 2015 · 63 citations · 24 references

DOIFull text

Open access

Abstract

The combination of PRi + MEKi can be an effective regimen for blocking proliferation of NRAS mutant melanomas when there is higher activity of the MAPK pathway and dependence of proliferation and survival on this pathway.

References

24

Bioconductor: open software development for computational biology and bioinformatics

Robert Gentleman, Vincent J. Carey, Douglas M. Bates et al. · Genome biology · 2004 · 12.4K citations · Full text

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

Keith T. Flaherty, J. Infante, Adil Daud et al. · New England Journal of Medicine · 2012 · 2.8K citations · Full text

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Gideon Bollag, Peter Hirth, James Tsai et al. · Nature · 2010 · 1.8K citations

, , +7

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

Sonja J. Heidorn, Carla Milagre, Steven R. Whittaker et al. · Cell · 2010 · 1.5K citations · Full text

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

Richard S. Finn, Judy Dering, Dylan Conklin et al. · Breast Cancer Research · 2009 · 1.4K citations · Full text